1 |
Cao Y, Xu P, Shen Y, Wu W, Chen M, Wang F, Zhu Y, Yan F, Gu W, Lin Y. Exosomes and cancer immunotherapy: A review of recent cancer research. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1118101] [Reference Citation Analysis]
|
2 |
Yu WF, Wang XQ, Zhao LP, Zhou JY, Feng JH. Down-regulation of IL-32γ expression reduces killing effect of natural killer cells on esophageal carcinoma cells. Shijie Huaren Xiaohua Zazhi 2022; 30(22): 990-996 [DOI: 10.11569/wcjd.v30.i22.990] [Reference Citation Analysis]
|
3 |
Lucotti S, Kenific CM, Zhang H, Lyden D. Extracellular vesicles and particles impact the systemic landscape of cancer. EMBO J 2022;:e109288. [PMID: 36052513 DOI: 10.15252/embj.2021109288] [Reference Citation Analysis]
|
4 |
Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol 2022;15:83. [PMID: 35765040 DOI: 10.1186/s13045-022-01305-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
5 |
Papak I, Chruściel E, Dziubek K, Kurkowiak M, Urban-wójciuk Z, Marjański T, Rzyman W, Marek-trzonkowska N. What Inhibits Natural Killers’ Performance in Tumour. IJMS 2022;23:7030. [DOI: 10.3390/ijms23137030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
6 |
Hosseini R, Sarvnaz H, Arabpour M, Ramshe SM, Asef-Kabiri L, Yousefi H, Akbari ME, Eskandari N. Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy. Mol Cancer 2022;21:15. [PMID: 35031075 DOI: 10.1186/s12943-021-01492-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
|